Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Extreme Bipolar Androgen Therapy With Darolutamide and Testosterone Cypionate in Patients With Metastatic Castration-Resistant Prostate Cancer (ExBAT Trial)

NCT04558866 is registered in ClinicalTrials.gov with Latin American Cooperative Oncology Group as lead sponsor.

NCT NCT04558866
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04558866 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Extreme Bipolar Androgen Therapy With Darolutamide and Testosterone Cypionate in Patients With Metastatic Castration-Resistant Prostate Cancer (ExBAT Trial)
Lead sponsor
Latin American Cooperative Oncology Group
Phase
Phase 2
Overall status
Completed
Start date
June 9, 2021
Completion date
April 2, 2024
Enrollment
51 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer